Exobiosphere

Exobiosphere develops biopharmaceutical solutions, utilizing unique space-based technologies for drug discovery, particularly in microgravity environments, targeting advancements in disease modeling and therapeutic development. Exobiosphere is focused on creating advanced biopharmaceutical solutions through its innovative Orbital High-Throughput System. Founded in 2024 by Kyle Acierno (CEO), Bruno Santos, and Olivia Borgue, the company is headquartered in Esch-sur-Alzette, Luxembourg. Recently, Exobiosphere secured EUR 2 million in Seed funding on March 5, 2025, led by Expansion Ventures, with participation from Boryung Biopharma Co.

, Ltd. , Expon Capital, and SpaceData Inc. Exobiosphere specializes in advanced biopharmaceutical solutions through its core offering, the Orbital High-Throughput System. This technology supports large-scale, automated testing in space, enabling the development of microgravity-based disease models.

By utilizing microgravity, the company enhances drug discovery processes, allowing researchers to identify novel molecular targets and characterize disease traits with improved accuracy. Exobiosphere serves a diverse clientele, including pharmaceutical companies and research institutions, particularly in North America, Europe, and Asia. Exobiosphere's revenue model is centered around partnerships with pharmaceutical companies and research institutions, primarily through B2B transactions. The company generates income via contracts for research services, which may involve subscriptions for access to its high-throughput screening capabilities.

Their focus on oncology, neuro-degeneration, and other therapeutic areas allows for tailored offerings to meet client needs, with pricing defined by project scope and service level requirements. In March 2025, Exobiosphere raised EUR 2 million in Seed funding, which will be allocated to finalize their space-based research platform, expand their team, and prepare for initial orbital missions. The company is expected to develop new products aimed at enhancing its biopharmaceutical capabilities and exploring additional markets, particularly targeting North America and Asia by the end of 2026.